Literature DB >> 23361905

Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms.

James A Kennedy1, Eshetu G Atenafu, Hans A Messner, Kenneth J Craddock, Joseph M Brandwein, Jeffrey H Lipton, Mark D Minden, Aaron D Schimmer, Andre C Schuh, Karen W Yee, Vikas Gupta.   

Abstract

Leukemic transformation (LT) is a rare but fatal complication of Philadelphia-negative myeloproliferative neoplasms (MPNs) for which optimal treatment strategies are not known. At our center, we have adopted a treatment approach for LT where patients within the transplant age group who have a reasonable fitness level are treated with curative intent and offered induction chemotherapy. Subsequently, those who respond and have a suitable donor are considered for allogeneic hematopoietic cell transplantation (HCT). In this study, we evaluated the clinical outcomes of this treatment approach in 75 patients with LT. The 2-year overall survival (OS) from the time of LT was 15%. A total of 39 patients (52%) were treated with curative intent (induction ± HCT) and had a 2-y OS of 26% compared with 3% in those noncuratively treated (P < .0001). In the curative intent group, 18 individuals (46%) achieved complete remission (CR) or CR with incomplete recovery and 12 (31%) reverted to a chronic MPN phase, with 17 patients undergoing HCT. Survival of patients posttransplant was significantly improved compared with those who responded to induction but were not transplanted (2-y OS of 47% vs 15%; P = .03). Thus, induction chemotherapy followed by HCT has the potential for long-term disease control in select patients with LT preceded by a MPN.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23361905     DOI: 10.1182/blood-2012-10-464248

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable.

Authors:  Lisa A Raedler
Journal:  Am Health Drug Benefits       Date:  2014-10

2.  Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.

Authors:  Raajit K Rampal; John O Mascarenhas; Heidi E Kosiorek; Leah Price; Dmitriy Berenzon; Elizabeth Hexner; Camille N Abboud; Marina Kremyanskaya; Rona Singer Weinberg; Mohamed E Salama; Kamal Menghrajani; Vesna Najfeld; Lonette Sandy; Mark L Heaney; Ross L Levine; Ruben A Mesa; Amylou C Dueck; Judith D Goldberg; Ronald Hoffman
Journal:  Blood Adv       Date:  2018-12-26

Review 3.  Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Tiziano Barbui; Omar Abdel-Wahab; Robert Kralovics; Catriona Jamieson; Hans-Michael Kvasnicka; Ann Mullaly; Raajit Rampal; Ruben Mesa; Jean-Jacques Kiladjian; Michael Deininger; Josef Prchal; Rüdiger Hehlmann; Giuseppe Saglio; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-11-19

Review 4.  Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Authors:  N M Kröger; J H Deeg; E Olavarria; D Niederwieser; A Bacigalupo; T Barbui; A Rambaldi; R Mesa; A Tefferi; M Griesshammer; V Gupta; C Harrison; H Alchalby; A M Vannucchi; F Cervantes; M Robin; M Ditschkowski; V Fauble; D McLornan; K Ballen; U R Popat; F Passamonti; D Rondelli; G Barosi
Journal:  Leukemia       Date:  2015-08-21       Impact factor: 11.528

5.  Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.

Authors:  T Tsuruta-Kishino; J Koya; K Kataoka; K Narukawa; Y Sumitomo; H Kobayashi; T Sato; M Kurokawa
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

6.  Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase.

Authors:  Vikas Gupta; James A Kennedy; Jose-Mario Capo-Chichi; Soyoung Kim; Zhen-Huan Hu; Edwin P Alyea; Uday R Popat; Ronald M Sobecks; Bart L Scott; Aaron T Gerds; Rachel B Salit; H Joachim Deeg; Ryotara Nakamura; Wael Saber
Journal:  Blood Adv       Date:  2020-11-10

7.  Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).

Authors:  X Cahu; P Chevallier; A Clavert; F Suarez; M Michallet; L Vincent; S Vigouroux; D Blaise; C Mariette; K Bilger; M Robin; I Yakoub-Agha; R Peffault de Latour; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-03-10       Impact factor: 5.483

Review 8.  Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.

Authors:  Michael Tallarico; Olatoyosi Odenike
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

Review 9.  Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.

Authors:  Bing Li; John O Mascarenhas; Raajit K Rampal
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 10.  Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?

Authors:  Auro Viswabandya; Rebecca Devlin; Vikas Gupta
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.